IL-16 antagonists

Details IL-16 antagonists IL-16 antagonists

2007-06-19

2007-06-19

Allen, Marianne P. (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S017400, C530S329000, C424S085100, C424S085200

Reexamination Certificate

active

11167710

ABSTRACT:
In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.

REFERENCES:
patent: 5126433 (1992-06-01), Maddon et al.
patent: 5171838 (1992-12-01), Chiba
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5846933 (1998-12-01), Korngold et al.
patent: 6159463 (2000-12-01), Center et al.
patent: 6251864 (2001-06-01), Dower et al.
patent: WO 94/28134 (1994-12-01), None
patent: WO 96/40189 (1996-12-01), None
patent: WO 97/36606 (1997-10-01), None
Barnes, PJ. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol. 1998.101:S427-33.Abstract.
Kreisman H., Cohen C., Ghezzo H., Vickerson F., Frank H., Wolkove N. Combined therapy with ipratropium and theophylline in asthma. Ann Allegy. 1984. 52(2) 90-93. Abstract.
Benjamin et al., 1998, Development 125:1591-1598.
Vukicevic et al., 1996, PNAS USA 93:9021-9026.
Massague, 1987, Cell 49:437-8.
Pilbeam et al., 1993, Bone 14:717-720.
Skolnick et al., 2000, Trends in Biotech. 18:34-39.
Bork, 2000, Genome Research 10:398-400.
Doerks et al., 1998, Trends in Genetics 14:248-250.
Smith et al., 1997, Nature Biotechnology 15:1222-1223).
Brenner, 1999, Trends in Genetics 15:132-133.
Bork et al., 1996, Trends in Genetics 12:425-427.
Bowie et al, 1990, Science 247:1306-1310.
Wells, 1990, Biochemistry 29:8509-8517.
Harlow E., et al.,Antibodies, pp. 76-555, 1988.
Moreland et al.,Arthritis and Rheumatism, 39(9) (supplement): S244, 1996.
Panayi et al.,Arthritis and Rheumatism, 39(9) (supplement): S244, 1996.
Choy et al.,Arthritis and Rheumatism, 39(9) (supplement): S244, 1996.
Connolly et al.,Arthritis and Rheumatism, 39(9) (supplement): S245, 1996.
Wending et al.,Arthritis and Rheumatism, 39(9) (supplement): S245, 1996.
Reece et al.,Arthritis and Rheumatism, 39(9) (supplement): S245, 1996.
Keane, J. et al., Conservation of Structure and Function Between Human and Murine IL-161,2, The Journal of Immunology, 160: 5945-5954 (1998).
Carr, S. A. et al., “Protein and Carbohydrate Structural Analysis of a Recombinant Soluble CD4 Receptor by Mass Spectrometry”,The Journal of Biological Chemistry, 264(35): 21286-21295 (1989).
Baier, M. et al., “Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor”,Proc. Natl. Acad. Sci. USA, 94: 5273-5277 (1997).

Affiliated with

Also associated with

Rating

IL-16 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IL-16 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-16 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3808408